
Sanofi appoints Gary Nabel as chief scientific officer
pharmafile | November 16, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Nabel, Sanofi
Sanofi has announced the appointment of Dr Gary Nabel, senior VP, chief scientific officer and deputy to the president for Global R&D.
Nabel will report to the president of Global R&D Dr Elias Zerhouni, and will join the group’s Global Leadership Team. He will be based in Cambridge, Massachusetts.
Nabel joins Sanofi from the National Institutes of Health, where he served as director of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases since 1999.
“Dr Nabel’s impressive scientific record and experience will be extremely valuable to the Group”, declared Christopher Viehbacher, chief executive, Sanofi. “I am confident that with his leadership, we can drive R&D further towards tomorrow’s breakthrough discoveries.”
In his new position, Nabel will be responsible for assessing and co-ordinating Sanofi’s scientific direction for biopharmaceuticals, vaccines and animal health with a focus on improving translational approaches across Sanofi.
“I am honored and excited to join Dr Zerhouni and the Sanofi team,” said Nabel. “By strengthening our scientific base, we hope to accelerate the rational development of innovative treatments that will save lives and improve human health.”
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






